Piper Jaffray Companies assumed coverage on shares of Envision Healthcare (NYSE:EVHC) in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. The firm issued a neutral rating and a $35.00 price target on the stock.

Several other research firms have also recently commented on EVHC. BidaskClub cut Envision Healthcare from a sell rating to a strong sell rating in a research note on Thursday, August 17th. Jefferies Group set a $71.00 target price on Envision Healthcare and gave the company a buy rating in a research note on Thursday, August 24th. Bank of America reduced their target price on Envision Healthcare from $72.00 to $60.00 and set a buy rating for the company in a research note on Monday, October 9th. Canaccord Genuity reiterated a buy rating and set a $32.00 target price (down from $68.00) on shares of Envision Healthcare in a research note on Thursday, November 2nd. Finally, Citigroup cut Envision Healthcare from a buy rating to a neutral rating and set a $31.00 target price for the company. in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $46.06.

Envision Healthcare (EVHC) opened at $34.30 on Wednesday. The company has a market capitalization of $4,146.49, a P/E ratio of 10.59, a PEG ratio of 0.89 and a beta of 0.57. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.01. Envision Healthcare has a one year low of $23.77 and a one year high of $73.00.

Envision Healthcare (NYSE:EVHC) last released its earnings results on Tuesday, October 31st. The company reported $0.73 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.81 by ($0.08). The business had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Envision Healthcare had a negative net margin of 6.39% and a positive return on equity of 4.88%. The business’s quarterly revenue was up 142.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.13 earnings per share. sell-side analysts anticipate that Envision Healthcare will post 2.56 earnings per share for the current year.

Envision Healthcare declared that its Board of Directors has initiated a stock buyback program on Monday, September 18th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 4.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

A number of institutional investors and hedge funds have recently made changes to their positions in EVHC. Commonwealth Bank of Australia increased its position in Envision Healthcare by 24.3% in the second quarter. Commonwealth Bank of Australia now owns 2,096 shares of the company’s stock worth $130,000 after buying an additional 410 shares during the period. LMR Partners LLP acquired a new stake in Envision Healthcare in the second quarter worth $205,000. Palisade Capital Management LLC NJ acquired a new stake in Envision Healthcare in the third quarter worth $229,000. Cutter & CO Brokerage Inc. increased its position in Envision Healthcare by 11.1% in the second quarter. Cutter & CO Brokerage Inc. now owns 3,668 shares of the company’s stock worth $230,000 after buying an additional 367 shares during the period. Finally, Flinton Capital Management LLC increased its position in Envision Healthcare by 18.7% in the second quarter. Flinton Capital Management LLC now owns 4,464 shares of the company’s stock worth $280,000 after buying an additional 704 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Envision Healthcare (EVHC) Earns Neutral Rating from Analysts at Piper Jaffray Companies” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/envision-healthcare-evhc-earns-neutral-rating-from-analysts-at-piper-jaffray-companies/1769412.html.

About Envision Healthcare

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Analyst Recommendations for Envision Healthcare (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.